Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma
Open Access
- 20 August 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Abstract
Tumor mutation burden (TMB) is a useful biomarker to predict prognosis and the efficacy of immune checkpoint inhibitors (ICIs). In this study, we aimed to explore the prognostic value of TMB and the potential association between TMB and immune infiltration in lower-grade gliomas (LGGs). Somatic mutation and RNA-sequencing (RNA-seq) data were downloaded from the Cancer Genome Atlas (TCGA) database. TMB was calculated and patients were divided into high- and low-TMB groups. After performing differential analysis between high- and low-risk groups, we identified six hub TMB and immune-related genes that were correlated with overall survival in LGGs. Then, Gene Set Enrichment Analysis was performed to screen significantly enriched GO terms between the two groups. Moreover, an immune-related risk score system was developed by LASSO Cox analysis based on the six hub genes and was validated with the Chinese Glioma Genome Atlas dataset. Using the TIMER database, we further systematically analyzed the relationships between mutants of the six hub genes and immune infiltration levels, as well as the relationships between the immune-related risk score system and the immune microenvironment in LGGs. The results showed that TMB was negatively correlated with OS and high TMB might inhibit immune infiltration in LGGs. Furthermore, the risk score system could effectively stratify patients into low- and high-risk groups in both the training and validation datasets. Multivariate Cox analysis demonstrated that TMB was not an independent prognostic factor, but the risk score was. Higher infiltration of immune cells (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells) and higher levels of immune checkpoints (PD-1, CTLA-4, LAG-3, and TIM-3) were found in patients in the high-risk group. Finally, a novel nomogram model was constructed and evaluated to estimate the overall survival of LGG patients. In summary, our study provided new insights into immune infiltration in the tumor microenvironment and immunotherapies for LGGs.Keywords
Funding Information
- National Natural Science Foundation of China (81472355)
- Department of Science and Technology of Hunan Province (2014FJ6006)
This publication has 40 references indexed in Scilit:
- Tumor infiltrating immune cells in gliomas and meningiomasBrain, Behavior, and Immunity, 2016
- Immune checkpoint blockade in lymphoid malignanciesThe FEBS Journal, 2016
- Cancer immunotherapy: harnessing the immune system to battle cancerJournal of Clinical Investigation, 2015
- Polymorphisms of PRLHR and HSPA12A and risk of gastric and colorectal cancer in the Chinese Han populationBMC Gastroenterology, 2015
- Glioma Groups Based on 1p/19q,IDH, andTERTPromoter Mutations in TumorsNew England Journal of Medicine, 2015
- ImmPort: disseminating data to the public for the future of immunologyImmunologic Research, 2014
- Cytokine Receptor-Like Factor 1 (CRLF1) Protects against 6-Hydroxydopamine Toxicity Independent of the gp130/JAK Signaling PathwayPLOS ONE, 2013
- Loss of the repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of rapamycin pathwayProceedings of the National Academy of Sciences, 2013
- Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell linesJournal of Cellular Biochemistry, 2011
- L1Penalized Estimation in the Cox Proportional Hazards ModelBiometrical Journal, 2010